1
|
Quon H, Hasbini A, Cougnard J, Djafari L, Lacroix C, Abdulkarim B. Multivariate Assessment of Tumor Angiogenesis as a Prognostic Factor for Survival in Patients with Oligodendroglioma and Anaplastic Oligodendroglioma. Int J Radiat Oncol Biol Phys 2008. [DOI: 10.1016/j.ijrobp.2008.06.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
2
|
Rubie H, Frappaz D, Defachelles A, Ndiaye A, Dias N, Aerts I, Gentet J, Djafari L, Jaworski M, Vassal G, Geoerger B. Phase I study of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed malignant tumors. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.13553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Kurtz JE, Rousseau F, Meyer N, Delozier T, Serin D, Nabet M, Djafari L, Dufour P. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients. Oncology 2008; 73:210-4. [PMID: 18424884 DOI: 10.1159/000127411] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2007] [Accepted: 09/24/2007] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To evaluate the efficacy and toxicity of pegylated liposomal doxorubicin (PLD; Caelyx)-cyclophosphamide combination in older metastatic breast cancer patients. METHODS A multicenter phase II trial was conducted. Inclusion criteria were age 65-75 years, ECOG 0-1 and left ventricular ejection fraction > or =50%. First-line chemotherapy was given to metastatic breast cancer patients resistant to hormonal therapy. The treatment schedule was PLD 40 mg/m(2) and cyclophosphamide 500 mg/m(2) on day 1 every 4 weeks. Efficacy was the primary endpoint, while response duration and tolerance were the secondary endpoints. RESULTS Thirty-five patients (median age 71.3 years) were enrolled. No treatment-related death, no congestive heart failure or decrease in left ventricular ejection fraction and no febrile neutropenia were reported. TOXICITY grade 3 dyspnea was found in 1 patient, neutropenia in 11 patients (7 grade 3, 4 grade 4), grade 3 mucositis in 4 patients, grade 3 hand-foot syndrome in 1 patient and a generalized rash in 1 patient. An objective response (complete and partial response) was achieved in 10 (28.6%) patients and disease control in 24 (69%) with a progression-free survival of 8.8 months and a median overall survival of 20.3 months. CONCLUSION The PLD-cyclophosphamide combination is moderately active and safe in elderly metastatic breast cancer patients, but cannot be recommended routinely due to myelotoxicity and mucositis hazards.
Collapse
Affiliation(s)
- J E Kurtz
- Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Dufour PR, Rousseau F, Meyer N, Delozier T, Serin D, Nabet M, Djafari L, Kurtz J. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in elderly metastatic breast cancer patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.19565] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
19565 Background: Although the majority of metastatic breast cancer (MBC) patients (pts) responds to endocrine therapy, treatment failure is a concern, as well as front-line therapy for pts with ER/PR negative disease.The combination of anthracyclines (A) and cyclophosphamide (C) is active in younger pts, but cardiac toxicity of A in elderly MBC pts has to be considered. Pegylated liposomal doxorubicin (PLD) (Caelyx®) is active in MBC and has much less cardiotoxicity than A, and we present the preliminary data of the PLD/C in elderly MBC pts. Methods: This was a multicentric phase II trial. Inclusion criteria included: pts aged between 65 and 75, histologically proven measurable MBC, ECOG PS 0–1, LVEF = 50%, first-line chemotherapy for MBC. Prior adjuvant chemotherapy was allowed if stopped for = 6 or 12 months without and with anthracyclines, respectively. Endocrine therapy either in the adjuvant or metastatic setting had to be stopped for = 1 month. All pts gave a written informed consent. The treatment schedule was : PLD 40mg/m2 and C 500mg/m2 d1 every 4 weeks. Efficacy as well as response duration and tolerance were the primary and secondary end-points, respectively. Results: 35 patients were enrolled (Median age 71.3, range 65.6–75.9). A total of 166 cycles have been administered. The median number of cycles was 6 (range 1–9). No toxic death was reported, one patient died of diabetes mellitus decompensation. No congestive heart failure or decrease in LVEF was reported, although 1 pt experience grade 3 dyspnea and stopped treatment. Other (gr3–4) NCI-CTC toxicity included: neutropenia in 7 (gr3) and 3 (gr4) pts; gr3 mucositis (4). No febrile neutropenia was reported. Grade 3 hand-foot syndrome occurred in 1 pt, whereas treatment was stopped due to a generalized rash in 1 pt. An objective response (CR + PR) was achieved in 10 (28,6%) pts (1 CR and 8 PR), and a disease control in 24 (68.6%) with a progression free survival of 8.8 months and a median survival of 20.4 months Conclusions: The LPD-C combination is active in elderly MBC pts, with an acceptable toxicity profile. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. R. Dufour
- Centre Paul Strauss, Strasbourg, France; Institut Paoli-Calmettes,, Marseille, France; Hôpitaux Universitaires de Strasbourg,, Strasbourg, France; Centre Francois Baclesse, Caen, France; Clinique St. Catherine, Avignon, France; Clinique Claude Bernard, Metz, France; Schering-Plough, Levallois-Perret, France; Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - F. Rousseau
- Centre Paul Strauss, Strasbourg, France; Institut Paoli-Calmettes,, Marseille, France; Hôpitaux Universitaires de Strasbourg,, Strasbourg, France; Centre Francois Baclesse, Caen, France; Clinique St. Catherine, Avignon, France; Clinique Claude Bernard, Metz, France; Schering-Plough, Levallois-Perret, France; Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - N. Meyer
- Centre Paul Strauss, Strasbourg, France; Institut Paoli-Calmettes,, Marseille, France; Hôpitaux Universitaires de Strasbourg,, Strasbourg, France; Centre Francois Baclesse, Caen, France; Clinique St. Catherine, Avignon, France; Clinique Claude Bernard, Metz, France; Schering-Plough, Levallois-Perret, France; Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - T. Delozier
- Centre Paul Strauss, Strasbourg, France; Institut Paoli-Calmettes,, Marseille, France; Hôpitaux Universitaires de Strasbourg,, Strasbourg, France; Centre Francois Baclesse, Caen, France; Clinique St. Catherine, Avignon, France; Clinique Claude Bernard, Metz, France; Schering-Plough, Levallois-Perret, France; Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - D. Serin
- Centre Paul Strauss, Strasbourg, France; Institut Paoli-Calmettes,, Marseille, France; Hôpitaux Universitaires de Strasbourg,, Strasbourg, France; Centre Francois Baclesse, Caen, France; Clinique St. Catherine, Avignon, France; Clinique Claude Bernard, Metz, France; Schering-Plough, Levallois-Perret, France; Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - M. Nabet
- Centre Paul Strauss, Strasbourg, France; Institut Paoli-Calmettes,, Marseille, France; Hôpitaux Universitaires de Strasbourg,, Strasbourg, France; Centre Francois Baclesse, Caen, France; Clinique St. Catherine, Avignon, France; Clinique Claude Bernard, Metz, France; Schering-Plough, Levallois-Perret, France; Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - L. Djafari
- Centre Paul Strauss, Strasbourg, France; Institut Paoli-Calmettes,, Marseille, France; Hôpitaux Universitaires de Strasbourg,, Strasbourg, France; Centre Francois Baclesse, Caen, France; Clinique St. Catherine, Avignon, France; Clinique Claude Bernard, Metz, France; Schering-Plough, Levallois-Perret, France; Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - J. Kurtz
- Centre Paul Strauss, Strasbourg, France; Institut Paoli-Calmettes,, Marseille, France; Hôpitaux Universitaires de Strasbourg,, Strasbourg, France; Centre Francois Baclesse, Caen, France; Clinique St. Catherine, Avignon, France; Clinique Claude Bernard, Metz, France; Schering-Plough, Levallois-Perret, France; Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| |
Collapse
|
5
|
Frappaz D, Pierga J, Bay J, Fabbro M, Djafari L, Sunyach M. Phase I of high dose (HD) temozolomide (TMZ) with peripheral blood stem cell support (PBSCS) rescue in recurrent high grade glioma (HGG). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.12518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
12518 Background: Despite improvements obtained with frontline treatments prognosis of recurrent HGG still remains dismal. HD chemotherapy (CT) suggested a dose-effect relationship in lymphoma and germ cell tumors. HD of TMZ could be a promising way to overcome resistance of HGG to standard schedule of CT Methods: This phase I had as principal objective to determine the Maximal Tolerated Dose (MTD) of HD of TMZ with PBSCS rescue in patients with recurrent HGG under 60 year. The MTD was defined as dose level which 50% of patients (pts) treated experienced a DLT (Dose Limiting Toxicity).The dose escalation was planned for eight dose levels from 300 to 650mg/m2/day over 5 days with CSP reinfusion at D7 according to the Modified Continual Reassessment Method (MCRM). Treatment was administered for one cycle. Results: Eighteen eligible pts were treated with HD of TMZ, all had received prior radiotherapy, 11 pts previous CT. Overall HD TMZ was well tolerated for the 7 evaluated dose levels. The MTD was not yet reached. Not dose limiting toxicities were reported in 12 pts: grade 2: fatigue (6pts), cephalalgia (3pts), nausea (3pts) , skin eruption (2pts), mucositis, FUO, vomiting, diarrhea, zoster, dental abcess, lung infection, septicemia, hepatic. grade 3 bilirubinemia, grade 4 neutropenia (13pts) and thrombocytopenia (4pts). Dose Limiting Toxicities were reported in 2 pts, gr3 cytolysis at level 3 (400mg/m2/day ) 1pt and gr 3 arthritis at level 7 (600mg/m2) 1pt respectively . Main hematological toxicities were gr 4 neutropenia in 13 pts median duration was 8 days, 4 pts had gr4 thrombocytopenia lasting 5 days. All patients were evaluable for tumor response, 2 partial responses were observed at 550 and 600mg/m2 level, 5 pts had a stabilization and a disease progression was reported in 11 patients. Conclusions: This interim analysis demonstrated that HD of TMZ with CSP reinfusion is feasible and well tolerated in patients with recurrent HGG. Nevertheless limited activity reported could be related to a less depletion of O6 alkylguanine transferase with HD than with a protracted schedule. Accrual is still ongoing. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Frappaz
- Centre Leon Berard, Lyon, France; Institut Curie, Paris, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Val d’Aurelle, Montpellier, France; Schering-Plough, Levallois-Perret, France
| | - J. Pierga
- Centre Leon Berard, Lyon, France; Institut Curie, Paris, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Val d’Aurelle, Montpellier, France; Schering-Plough, Levallois-Perret, France
| | - J. Bay
- Centre Leon Berard, Lyon, France; Institut Curie, Paris, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Val d’Aurelle, Montpellier, France; Schering-Plough, Levallois-Perret, France
| | - M. Fabbro
- Centre Leon Berard, Lyon, France; Institut Curie, Paris, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Val d’Aurelle, Montpellier, France; Schering-Plough, Levallois-Perret, France
| | - L. Djafari
- Centre Leon Berard, Lyon, France; Institut Curie, Paris, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Val d’Aurelle, Montpellier, France; Schering-Plough, Levallois-Perret, France
| | - M. Sunyach
- Centre Leon Berard, Lyon, France; Institut Curie, Paris, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Val d’Aurelle, Montpellier, France; Schering-Plough, Levallois-Perret, France
| |
Collapse
|
6
|
Rubie H, Chishlom J, Defachelles A, Morland B, Munzer C, Valteau Couanet D, Hargrave D, Bergeron C, Coze C, Djafari L, Vassal G. Temozolomide phase II study in children with relapsing refractory high-risk neuroblastoma. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9012 Background: To determine the response rate (RR) of neuroblastoma (NB) in children to temozolomide (TMZ), and evaluate the duration of response and tolerance of the drug in this patient population. Methods: A multicenter, phase II evaluation of an oral, daily schedule of TMZ (200 mg/m2 on 5 consecutive days and repeated every 28 days) was undertaken in children with a refractory or relapsed high-risk NB (metastatic or localized with Myc-N amplification). Evidence of activity was defined by radiologic or MIBG scan evidence of sustained reduction in lesion size or activity whenever it occurs. Methodology included a two-step study using Fleming’s method with a first step of 15 patients and a second of 10 additional patients if 2 to 4 responses had been observed in the first cohort. All data were centrally reviewed by a panel. Results: Among 34 registered patients over a 14 month period in 14 centres, twenty five are finally evaluable and received 94 cycles of chemotherapy. Disease status was metastatic NB (n=23) either refractory (n=9) or in relapse (n=14). Grade ¾ thrombocytopenia was the most frequent toxic event (16% of the cycles). Myelosuppression resulted in significant treatment delays and dose reductions (24% and 21% of cycles respectively). Out of 25 patients, response (CR, VGPR or PR) was observed in 5 (RR=20 ± 8%) with a median duration of 6 months. Furthermore a mixed response or an objective effect was observed in respectively 2 and 3 additional patients. Conclusions: Temozolomide is effective in heavily pretreated patients with NB, and deserves further evaluation in combination with another drug No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Rubie
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| | - J. Chishlom
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| | - A. Defachelles
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| | - B. Morland
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| | - C. Munzer
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| | - D. Valteau Couanet
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| | - D. Hargrave
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| | - C. Bergeron
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| | - C. Coze
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| | - L. Djafari
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| | - G. Vassal
- Hôpital Enfants—Centre Hospitalo-Universitaire, Toulouse, France; Great Ormond Street Hospital, London, United Kingdom; Centre Oscar Lambret, Lille, France; Birmingham Children’s Hospital, Londres, United Kingdom; Institut Gustave Roussy, Villejuif, France; NewCastel Royal Infirmary, NewCastel, United Kingdom; Centre Leon Berard, Lyon, France; Hôpital pour Enfants—La Timone, Marseille, France; Laboratory Schering Plough, Paris, France
| |
Collapse
|
7
|
Geoerger B, Vassal G, Doz F, O'Quigley J, Wartelle M, Watson AJ, Raquin MA, Frappaz D, Chastagner P, Gentet JC, Rubie H, Couanet D, Geoffray A, Djafari L, Margison GP, Pein F. Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. Br J Cancer 2005; 93:529-37. [PMID: 16136028 PMCID: PMC2361608 DOI: 10.1038/sj.bjc.6602740] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Cisplatin may have additive activity with temozolomide due to ablation of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (MGMT). This phase I/II study determined recommended combination doses using the Continual Reassessment Method, toxicities and antitumour activity in paediatric patients, and evaluated MGMT in peripheral blood mononuclear cells (PBMCs) in order to correlate with haematological toxicity. In total, 39 patients with refractory or recurrent solid tumours (median age ∼13 years; 14 pretreated with high-dose chemotherapy, craniospinal irradiation, or having bone marrow involvement) were treated with cisplatin, followed the next day by oral temozolomide for 5 days every 4 weeks at dose levels 80 mg m−2/150 mg m−2 day−1, 80/200, and 100/200, respectively. A total of 38 patients receiving 113 cycles (median 2, range 1–7) were evaluable for toxicity. Dose-limiting toxicity was haematological in all but one case. Treatment-related toxicities were thrombocytopenia, neutropenia, nausea-vomiting, asthenia. Hearing loss was experienced in five patients with prior irradiation to the brain stem or posterior fossa. Partial responses were observed in two malignant glioma, one brain stem glioma, and two neuroblastoma. Median MGMT activity in PBMCs decreased after 5 days of temozolomide treatment: low MGMT activity correlated with increased severity of thrombocytopenia. Cisplatin–temozolomide combinations are well tolerated without additional toxicity to single-agent treatments; the recommended phase II dosage is 80 mg m−2 cisplatin and 150 mg m−2 × 5 temozolomide in heavily treated, and 200 mg m−2 × 5 temozolomide in less-heavily pretreated children.
Collapse
Affiliation(s)
- B Geoerger
- Department of Pediatrics, Institut Gustave Roussy, Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY. Initial chemotherapy in gliomatosis cerebri. Neurology 2004; 63:270-5. [PMID: 15277619 DOI: 10.1212/01.wnl.0000129985.39973.e4] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity. In this setting, initial chemotherapy warrants further investigation. METHODS The authors treated 63 consecutive patients with GC with initial chemotherapy consisting of either PCV (procarbazine, 60 mg/m2 on days 8 to 21; CCNU, 110 mg/m2 on day 1; and vincristine, 1.4 mg/m2 on days 8 and 29) or temozolomide (TMZ; 150 to 200 mg/m2 for 5 days every 4 weeks). There were 40 men and 23 women, with a median age of 48 years (range, 17 to 74 years) and a median Karnofsky performance status of 90 (range, 50 to 100). GC was initially present at diagnosis in 49 patients (primary GC), whereas 14 patients with a circumscribed glioma at onset developed secondary GC after a median follow-up period of 5.11 years. GC was classified based on the predominant tumor cells as astrocytic, oligodendroglial, or mixed GC. RESULTS Seventeen patients received 1 to 6 cycles (median, 5) of PCV, and 46 received 2 to 24 courses (median, 13) of TMZ. Grade 3 to 4 hematologic toxicity was seen in 4 of 17 (23.5%) patients treated with PCV and in 4 of 46 (8.6%) of those treated with TMZ. Clinical objective responses were observed in 21 of 63 (33%) patients, and radiologic responses were seen in 16 of 62 (26%), with no significant difference between the two regimens. For all patients combined, the median progression-free survival (PFS) and overall survival (OS) were 16 months and 29 months, respectively. Regardless of the chemotherapeutic regimen, oligodendroglial GC had a better prognosis than astrocytic and oligoastrocytic GC in terms of PFS (p < 0.02) and OS (p < 0.0001). CONCLUSION Initial chemotherapy is useful for some patients with gliomatosis cerebri. Temozolomide is well tolerated and appears to be a valuable alternative to procarbazine-CCNU-vincristine, especially for those with slow-growing, low-grade GC.
Collapse
Affiliation(s)
- M Sanson
- Fédération de neurologie Mazarin, Groupe hospitalier Pitié-Salpêtrière and Université Pierre et Marie Curie, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abdulkarim BS, Hasbini A, Cougnard J, Djafari L, Lacroix C, Parker F, Haie C, Cioloca C, Deutsch E, Raymond E. Baseline pathological and radiological assessment of tumor angiogenesis predicts survival in patients with oligodendrogliomas. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. S. Abdulkarim
- IGR, Villejuif, France; Shering-Plough, Levalois-Perret, France; Hopital Kremlin Bicetre, Kremlin Bicetre, France; Hopital Ste Anne, Paris, France
| | - A. Hasbini
- IGR, Villejuif, France; Shering-Plough, Levalois-Perret, France; Hopital Kremlin Bicetre, Kremlin Bicetre, France; Hopital Ste Anne, Paris, France
| | - J. Cougnard
- IGR, Villejuif, France; Shering-Plough, Levalois-Perret, France; Hopital Kremlin Bicetre, Kremlin Bicetre, France; Hopital Ste Anne, Paris, France
| | - L. Djafari
- IGR, Villejuif, France; Shering-Plough, Levalois-Perret, France; Hopital Kremlin Bicetre, Kremlin Bicetre, France; Hopital Ste Anne, Paris, France
| | - C. Lacroix
- IGR, Villejuif, France; Shering-Plough, Levalois-Perret, France; Hopital Kremlin Bicetre, Kremlin Bicetre, France; Hopital Ste Anne, Paris, France
| | - F. Parker
- IGR, Villejuif, France; Shering-Plough, Levalois-Perret, France; Hopital Kremlin Bicetre, Kremlin Bicetre, France; Hopital Ste Anne, Paris, France
| | - C. Haie
- IGR, Villejuif, France; Shering-Plough, Levalois-Perret, France; Hopital Kremlin Bicetre, Kremlin Bicetre, France; Hopital Ste Anne, Paris, France
| | - C. Cioloca
- IGR, Villejuif, France; Shering-Plough, Levalois-Perret, France; Hopital Kremlin Bicetre, Kremlin Bicetre, France; Hopital Ste Anne, Paris, France
| | - E. Deutsch
- IGR, Villejuif, France; Shering-Plough, Levalois-Perret, France; Hopital Kremlin Bicetre, Kremlin Bicetre, France; Hopital Ste Anne, Paris, France
| | - E. Raymond
- IGR, Villejuif, France; Shering-Plough, Levalois-Perret, France; Hopital Kremlin Bicetre, Kremlin Bicetre, France; Hopital Ste Anne, Paris, France
| |
Collapse
|
10
|
Vera K, Djafari L, Faivre S, Guillamo JS, Djazouli K, Osorio M, Parker F, Cioloca C, Abdulkarim B, Armand JP, Raymond E. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol 2004; 15:161-71. [PMID: 14679137 DOI: 10.1093/annonc/mdh003] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150-200 mg/m(2)/day on days 1-5 every 4 weeks. In this study, a new alternative dose-dense regimen of temozolomide was explored in patients with recurrent brain tumors. PATIENTS AND METHODS In this study, we evaluated the safety, dose-limiting toxicity, maximum tolerated dose, recommended dose and activity of temozolomide given on days 1-3 and 14-16 every 28 days (one cycle). The starting daily dose was 200 mg/m(2) in a group of at least six patients, with subsequent increments of 50 mg/m(2) in groups of at least 12 patients until unacceptable toxicity was reached. Oral ondansetron (8 mg) was given 1 h prior to temozolomide administration. McDonald's criteria were used to evaluate antitumor activity. RESULTS Seventy patients with brain tumors entered this study. The median number of prior chemotherapy treatments was two (range 1-3). Patients were assigned to one of four groups to receive temozolomide at daily doses of 200 (seven patients), 250 (13 patients), 300 (38 patients) and 350 mg/m(2)/day (12 patients). The absence of dose-limiting toxicity at cycle 1 led us to establish dose recommendations based on toxicity after repeated cycles. A total of 23, 72, 192 and 83 cycles were given at daily doses of 200, 250, 300 and 350 mg/m(2), respectively. Grade 3-4 thrombocytopenia was observed in 0/7, 1/13, 5/38 and 4/12 patients treated at doses of 200, 250, 300 and 350 mg/m(2)/day, respectively. Grade 3-4 neutropenia was observed in 1/7, 0/13, 3/38 and 4/12 patients treated with 200, 250, 300 and 350 mg/m(2)/day temozolomide, respectively. At a dose of 350 mg/m(2), sustained grade 2-3 thrombocytopenia did not allow treatment to be resumed at day 14 in >40% of patients, and this dose was considered to be the maximum tolerated dose. Thus, a dose of 300 mg/m(2)/day that was associated with <20% treatment delay due to sustained hematological toxicity was considered as the recommended dose. Objective responses were reported in 13 patients. CONCLUSIONS Temozolomide can be given safely using a dose-dense regimen of 300 mg/m(2)/day for 3 consecutive days every 2 weeks in patients with recurrent brain tumors.
Collapse
Affiliation(s)
- K Vera
- Department of Medicine, Institute Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|